X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ASTRAZENECA PHARMA VENUS REMEDIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x -4.8 157.6 - View Chart
P/BV x 0.2 24.5 0.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,285 9.8%   
Low Rs61634 9.6%   
Sales per share (Unadj.) Rs301.8189.6 159.2%  
Earnings per share (Unadj.) Rs-24.9-0.2 12,215.3%  
Cash flow per share (Unadj.) Rs2.53.8 66.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.368.6 427.3%  
Shares outstanding (eoy) m12.3425.00 49.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.1 6.1%   
Avg P/E ratio x-3.8-4,712.7 0.1%  
P/CF ratio (eoy) x36.7249.6 14.7%  
Price / Book Value ratio x0.314.0 2.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15423,988 4.8%   
No. of employees `0000.91.6 59.3%   
Total wages/salary Rs m3931,605 24.5%   
Avg. sales/employee Rs Th4,026.13,040.2 132.4%   
Avg. wages/employee Rs Th425.01,029.2 41.3%   
Avg. net profit/employee Rs Th-331.8-3.3 10,162.1%   
INCOME DATA
Net Sales Rs m3,7244,740 78.6%  
Other income Rs m2392 24.4%   
Total revenues Rs m3,7474,832 77.5%   
Gross profit Rs m395-130 -304.2%  
Depreciation Rs m338101 334.3%   
Interest Rs m3540-   
Profit before tax Rs m-275-139 198.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m325 620.8%   
Profit after tax Rs m-307-5 6,029.5%  
Gross profit margin %10.6-2.7 -387.1%  
Effective tax rate %-11.5-3.7 313.2%   
Net profit margin %-8.2-0.1 7,673.8%  
BALANCE SHEET DATA
Current assets Rs m2,6382,726 96.7%   
Current liabilities Rs m2,3052,435 94.6%   
Net working cap to sales %8.96.1 145.5%  
Current ratio x1.11.1 102.2%  
Inventory Days Days13574 183.6%  
Debtors Days Days4641 113.7%  
Net fixed assets Rs m4,8711,035 470.5%   
Share capital Rs m12350 246.8%   
"Free" reserves Rs m3,496942 370.9%   
Net worth Rs m3,6191,716 210.9%   
Long term debt Rs m1,3740-   
Total assets Rs m7,5094,156 180.7%  
Interest coverage x0.2NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.1 43.5%   
Return on assets %0.6-0.1 -515.4%  
Return on equity %-8.5-0.3 2,858.9%  
Return on capital %1.60-  
Exports to sales %05.7 0.0%   
Imports to sales %13.96.5 214.6%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs m517306 168.6%   
Fx inflow Rs m0375 0.0%   
Fx outflow Rs m517470 109.9%   
Net fx Rs m-517-96 540.6%   
CASH FLOW
From Operations Rs m514-8 -6,350.6%  
From Investments Rs m-123-146 84.5%  
From Financial Activity Rs m-387862 -44.9%  
Net Cashflow Rs m4709 0.6%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 0.3 60.0%  
FIIs % 0.6 15.7 3.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 9.1 729.7%  
Shareholders   20,121 12,856 156.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS